华亿体育(中国)游戏平台华亿体育(中国)游戏平台

0571-87968248 CHINESE
  • Home
  • About us
    ProfileCultureHistory
  • News
    Company newsTrade showsIndustry news
  • Products
    COVID-19 IgG/IgM Rapid Test KitAllergen-specific IgE antibodies test kit seriesFood-specific IgG/IgG4 antibodies test seriesSingle/Polynomial allergen test seriesSingle allergen component test seriesGenetic test for allergic diseases series productsOther seriesProduct specific equipment
  • About allergies
    Scientific literaturePopular scienceVideos
  • Contact us
    Join usContact us
Scientific literaturePopular scienceVideos
Components literatureGene literatureMechanism literatureProbioticsTest literatureDesensitizationOther

Release date:2020-09-04


Allergy
[IF:6.771]
Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: 
A randomized controlled trial
DOI: 10.1111/all.14218
Abstract:
Background: Artemisia annua is an important autumnal pollen allergen for seasonal allergic rhinitis (SAR) in northern China. To date, no study has investigated allergen immunotherapy with A annua. We aimed to investigate the efficacy and mechanisms underlying A annua-sublingual immunotherapy (SLIT).
Methods: This was a randomized, double-blind, placebo-controlled phase III clinical trial involving 71 SAR patients, randomized to SLIT with A annua extract (n = 47) or placebo (n = 24) for 32 weeks. Total nasal symptom score (TNSS; primary clinical end point) was evaluated at baseline (peak pollen phase (PPP) in the previous year), initiation of A annua-SLIT, 1st PPP during SLIT, end of SLIT and 2nd PPP during follow-up. Blood samples and nasal secretions were collected at beginning and after SLIT for assessment of T cells and inflammatory mediators. Safety was assessed according to adverse events (AEs) reported.
Results: Artemisia annua-SLIT significantly reduced TNSS to a greater level from baseline (from 9.45 ± 1.68 to 6.16 ± 2.27) than placebo (from 9.29 ± 2.09 to 9.05 ± 2.40) at the 1st PPP (P < .001) and sustained the improvement in symptoms throughout to the 2nd PPP. Preseasonal A annua-SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased cystatin 1 (CST1) in nasal secretion after 16 and 32 weeks compared with pretreatment. Overall, 17/47 patients experienced mild local AEs and 2 patients mild systemic AEs, after A annua-SLIT.
Conclusion: Artemisia annua-SLIT is an efficacious and safe treatment in patients with A annua SAR.
First Author:
Hongfei Lou,  Chengshuo Wang
Correspondence:
Chengshuo Wang, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No.1, Dongjiaominxiang, DongCheng District, Beijing 100730, China.
All Authors:
Hongfei Lou, Yanran Huang,Yuhui Ouyang,Yuan Zhang, Lin Xi, Xiaohan Chu, Yang Wang, Chengshuo Wang, Luo Zhang
2020-08-19 Article
  • Home
  • About us
  • News
  • Products
  • About allergies
  • Contact us
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd.  Copyright    HZKC Technical support   浙ICP备14005341号   (浙)-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist.      Tel: 0571-87968248-805     Website:www.martscope.com

COPYRIGHT©2003-2024 www.martscope.com CORPORATION. ALL RIGHTS RESERVED

Official WeChat

开云电子(中国)官方网站 | 华亿首页(中国)网页版 | 开云网页版 | 天博手机网页(中国)有限公司 | 千亿体育线上平台中国有限公司 | 米兰手机在线登入 | 米乐官方网页版 | 华亿网页版 | 三亿体育首页(中国)网站首页 |